Denali Therapeutics Stock Forecast

Stock Price Forecast

According to 19 analysts polled by S&P Global, Denali Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $33.93. The average 1-year stock price forecast is 45.56% higher than the current stock price, while the lowest is $20 (-14.20%) and the highest is $42 (+80.18%).

Price Target: $33.93 (+45.56%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$20	$33.93	$35	$42
Change	-14.20%	+45.56%	+50.15%	+80.18%

Analyst Ratings

The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	17	17	17	17	17	17
Buy	1	1	1	1	1	1
Hold	0	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	18	19	19	19	19	19

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Maintains $40 → $35	Buy	Maintains	$40 → $35	+50.15%	May 26, 2026
Myles Minter William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 22, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 22, 2026
Unknown Analyst Jefferies No rating	Jefferies	Buy Maintains $40	Buy	Maintains	$40	+71.60%	May 22, 2026
David Hoang Deutsche Bank	Deutsche Bank	Buy Maintains $35 → $31	Buy	Maintains	$35 → $31	+32.99%	May 22, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

41.00M

Revenue Next Year

113.17M

from 41.00M

176.03%

from 41.00M

EPS This Year

-2.32

from -2.97

EPS Next Year

-2.48

from -2.32

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	48.66M	108.46M	330.53M	-	-	41.00M
Gross Profit	-216.69M	-250.27M	-93.35M	-396.44M	-418.78M	37.97M
Gross Margin	-445.31%	-230.74%	-28.24%	-	-	92.61%
Operating Income	-295.75M	-340.74M	-196.70M	-501.88M	-555.34M	-538.35M
Net Income	-290.58M	-325.99M	-145.22M	-422.77M	-512.54M	-481.15M
EPS	-	-	-	-	-2.97	-2.32
Free Cash Flow	200.41M	-141.03M	-298.35M	-200.74M	-244.19M	-277.20M
No. Analysts	-	-	-	-	-	18

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	237.6M
Avg	41.0M
Low	4.3M

Revenue Growth

Revenue Growth	2027	2028
High	433.9%
Avg	176.0%
Low	-14.6%

EPS Forecast

EPS	2026	2027	2028
High	-1.21
Avg	-2.32
Low	-2.97

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-